Welsh AMD network established

Article

An ophthalmology network, aiming to prevent loss of vision across the country, has been established in Wales.

An ophthalmology network, aiming to prevent loss of vision across the country, has been established in Wales.

As of November 20, Lucentis (ranibizumab; Novartis) for the treatment of age-related macular degeneration (AMD) in both eyes has been available on the National Health Service (NHS) in Wales. The availability and reimbursement of Lucentis has exerted increasing pressure on the services available in the country. In response, the government has established the nine-centre hospital-based network, and plans to increase staff levels this month, both to ensure long-term training and expertise in the treatment of AMD and to establish a uniform quality of eye care throughout Wales. Health Minister Edwina Hart has also announced a £15 million (€17.9 million) commitment to fund Lucentis in 2009 and 2010.

Eight of the nine treatment centres in the ophthalmology network are already treating patients. The ninth will be located in Amman Valley Hospital in Ammanford, Carmarthenshire.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.